Dementia and Geriatric Cognitive Disorders最新文献

{"title":"Sleep Apnea Risk, Subjective Cognitive Decline, and Cognitive Performance: Findings from the Boston Latino Aging Study.","authors":"Celina McDowell, Averi Giudicessi, Jairo Enrique Martinez, Alex L Badillo-Cabrera, Nikole A Bonillas Félix, Lusiana Martinez, Diana Munera, Clara Vila-Castelar, Nadine Schwab, Liliana Ramirez-Gomez, Daniel Gilberto Saldana, Marta Gonzalez Catalan, Rebecca Amariglio, Jeanne F Duffy, Alice Cronin-Golomb, Yakeel T Quiroz","doi":"10.1159/000542691","DOIUrl":"10.1159/000542691","url":null,"abstract":"<p><strong>Introduction: </strong>Obstructive sleep apnea (OSA) is associated with subjective cognitive decline (SCD) and increased risk of cognitive decline and dementia. These relations are understudied in ethnoracially diverse groups. We examined associations among self-reported OSA risk, SCD, and cognitive performance in community-dwelling older Latinos. High OSA risk was hypothesized to be associated with greater SCD and worse cognitive performance.</p><p><strong>Methods: </strong>112 participants (40 female) from the Boston Latino Aging Study (BLAST) were included (Mage = 67.0 years [SD = 8.0]; Meducation = 11.0 years [SD = 5.1]). Participants completed the Preclinical Alzheimer's Cognitive Composite-5 (PACC5; z-scores), the Berlin Questionnaire (high vs. low OSA risk), and the Cognitive Function Instrument (SCD). The Mini-Mental State Examination (MMSE) indexed global cognition. Hierarchical regressions assessed associations among OSA risk, SCD, and cognitive performance while controlling for demographics. t tests examined demographic and cognitive differences between those at high/low OSA risk.</p><p><strong>Results: </strong>On average, participants had an MMSE score of 25.9 (SD = 3.7, range 11-30; 37 participants with MMSE <26) and mild SCD (CFI; M = 4.2 [3.6]). OSA risk did not predict SCD (β = 0.09, p = 0.33) or PACC5 performance (β = 0.01, p = 0.92). No differences in SCD or PACC5 performance were observed between those at low versus high OSA risk (p's ≥ 0.21).</p><p><strong>Conclusion: </strong>Preliminary findings suggest that self-reported OSA risk may not signal cognitive decline risk for older Latinos. Questionnaires screening for OSA may need to be used in tandem with other assessments to identify those experiencing early cognitive decline. More work with larger sample sizes is needed; BLAST data collection is ongoing.</p>","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":" ","pages":"1-7"},"PeriodicalIF":2.2,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyperbaric Oxygen Therapy Improves Motor Symptoms, Sleep, and Cognitive Dysfunctions in Parkinson's Disease.","authors":"Shiying Bu, Wuchao Liu, Xia Sheng, Lingjing Jin, Qing Zhao","doi":"10.1159/000542619","DOIUrl":"10.1159/000542619","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to systematically analyze the therapeutic effectiveness of hyperbaric oxygen therapy compared with conventional drug therapy in patients with Parkinson's disease.</p><p><strong>Methods: </strong>PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang Database searched to the end of March 2023. Two authors independently screened and abstracted data from each trial. The primary outcome measures included the efficacy rate and the Unified Parkinson's Disease Rating Scale III (UPDRS III). Secondary outcome measures included the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), Hamilton Depression Scale (HAMD), Minimum Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Hoehn-Yahr staging.</p><p><strong>Results: </strong>Thirteen studies with a total of 958 participants were included in the meta-analysis. After intervention, the experimental group exhibited a higher treatment efficacy rate compared to the control group (odds ratio = 3.18, 95% confidence interval [95% CI; 1.60, 6.33], p < 0.01), a lower UPDRS III score (mean difference [MD] = -2.96, 95% CI [-4.31, -1.61], p < 0.01), and lower Hoehn-Yahr staging (MD = -0.14, 95% CI [-0.26, -0.02], p < 0.01). The experimental group also outperformed the control group in non-motor symptoms, with higher scores in MoCA, PSQI, and ESS (standardized MD = 0.65, 95% CI [0.45, 0.85], p < 0.01), (MD = -2.52, 95% CI [-2.85, -2.18], p < 0.01), and (MD = -3.30, 95% CI [-3.77, -2.83], p < 0.01), respectively.</p><p><strong>Conclusion: </strong>Hyperbaric oxygen therapy improves motor function, relieves the severity of the disease, ameliorates cognitive function, and improves sleep quality while alleviating excessive daytime sleepiness in patients with Parkinson's disease. The therapeutic mechanism of hyperbaric oxygen therapy may be related to increased cerebral tissue oxygen content, which contributes to anti-hypoxic, anti-inflammatory, anti-apoptotic, and antioxidant stress.</p>","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":" ","pages":"1-14"},"PeriodicalIF":2.2,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association of Impaired Vibration Sensation in the Lower Limb with Tests of Cognition in Older People: The Cardiovascular Health Study.","authors":"Joshua I Barzilay, Petra Buzkova, William T Longstreth, Oscar Lopez, David Bleich, David Siscovick, Anne Newman, Shohinee Sarma, Kenneth J Mukamal","doi":"10.1159/000542523","DOIUrl":"10.1159/000542523","url":null,"abstract":"<p><strong>Introduction: </strong>The prevalence of peripheral neuropathy (PN) in the lower limb increases with age and with the presence of diabetes. Studies show an association of PN with advanced cognitive impairment. Here we examine the association of PN with measures of early cognitive deficits in a cohort of older adults without apparent cognitive impairment, with or without diabetes.</p><p><strong>Methods: </strong>A total of 2,798 participants from the Cardiovascular Health Study were examined, mean age 80 years. All underwent tests of overall cognition (3MSE), executive function (DSST), and visual memory (BVRT). Impairment of vibration sensation in the toes, ankles, and tibial tuberosities was ascertained. Participants were graded according to the extent of impairment. Adjusted linear regression analyses of the extent of impaired vibration sensation with cognitive tests were performed. Results were further categorized by the presence or absence of diabetes.</p><p><strong>Results: </strong>70% of participants had intact vibration sensation in the toes; 8% had no vibration sensation in the tibial tuberosities or below. Compared to participants with intact vibration sensation in the toes, those with no vibration sensation in the tibial tuberosities had lower 3MSE scores. Tests of executive function were lower in a stepwise manner with greater impaired vibration sensation. Visual memory was less strongly associated with impaired vibration sensation. Findings did not differ significantly by diabetes status.</p><p><strong>Conclusion: </strong>In older adults, impaired vibration sensation in the lower limb is associated with impaired executive function and visual memory. These findings did not differ by diabetes status.</p>","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12086257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of the Music Therapy in Dementia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Li-Chin Lu, Shao-Huan Lan, Shou-Jen Lan, Yen-Ping Hsieh","doi":"10.1159/000542464","DOIUrl":"10.1159/000542464","url":null,"abstract":"<p><strong>Introduction: </strong>Studies have comprehensively examined key variables in music therapy (MT) interventions such as exposure time, session length, and frequency, particularly in relation to patients with dementia. This study investigated the effects of MT on cognitive function, depression, anxiety, behavior, and quality of life in individuals with dementia.</p><p><strong>Methods: </strong>Relevant articles published before April 23, 2023, were sourced from five databases, including PubMed, Web of Science, and Embase. Only randomized controlled trials (RCTs) comparing the effects of MT and standard care on the cognitive function, depression levels, anxiety levels, behaviors, and quality of life of individuals with dementia were included. The Reviewers independently extracted data and assessed the studies' methodological quality. Heterogeneity was quantified using Q statistics from χ2 tests and I2 statistics. Outcome analysis was conducted using a random-effects model, and the standardized mean difference, mean difference, and 95% confidence interval were calculated.</p><p><strong>Results: </strong>A total of 24 RCTs were included. Compared with the control group, patients who received MT had higher cognitive function, lower levels of depression, and lower levels of anxiety. Meta-regression analysis revealed that the total MT period, total number of MT sessions, weekly MT frequency, MT exposure time, and length of each MT session were associated with an improvement in cognitive function. However, no significant difference was observed in behaviors or quality of life.</p><p><strong>Conclusions: </strong>MT yielded improved cognitive function in individuals with dementia if the intervention spans at least 12 weeks, has at least 16 sessions, and has at least 8 h of therapy.</p>","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":" ","pages":"1-20"},"PeriodicalIF":2.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and Psychometric Properties of Integrated Care for Older People Screening Tool for Taiwanese (ICOPES-TW) Cognitive Screening Test.","authors":"Chung-Ying Lin, Hua-Lin Liu, Yi-Ching Yang, Jung-Der Wang, Chung-Yi Li, Mark D Griffiths, Li-Fan Liu","doi":"10.1159/000542272","DOIUrl":"10.1159/000542272","url":null,"abstract":"<p><strong>Background: </strong>Intrinsic capacity, a concept proposed by the World Health Organization, includes multidimensions to better understand older adults' health conditions for successful healthy aging. One of the key dimensions of intrinsic capacity is cognition. The present study aimed to examine if the cognitive test in Integrated Care for Older People Screening Tool for Taiwanese (ICOPES-TW) is a suitable instrument for screening cognition impairment.</p><p><strong>Methods: </strong>Older adults from community or medical center settings in Tainan were recruited (n = 553; mean ± SD age = 75.80 ± 8.32; 60.8% females). All participants were administered the ICOPES-TW cognitive test, the Mini-Mental State Examination (MMSE), Lawton Instrumental Activities of Daily Living (IADL), and Barthel Index (BI) in an in-person interview conducted by a well-trained research assistant.</p><p><strong>Results: </strong>The ICOPES-TW cognitive test was highly correlated with the MMSE total score (r = -0.752) and moderately correlated with IADL (r = -0.426) and BI scores (r = -0.390). When using a cutoff score of 1 for the ICOPES-TW cognitive test, its accuracy to identify cognitive impairment defined by the MMSE was 60% (sensitivity = 0.98, specificity = 0.41). When using cutoff score of 2, the accuracy was 83% (sensitivity = 0.69, specificity = 0.90). Moreover, the ICOPES-TW cognitive test had similar properties to the MMSE in terms of known-group validity (distinguishing different age and educational level groups).</p><p><strong>Conclusions: </strong>Using ICOPES-TW cognitive test with appropriate cutoff point in different healthcare settings could help providers and researchers quickly identify if an older adult has a cognitive impairment. However, the screening ability of ICOPES-TW cognitive test was deemed fair but future studies are recommended to help improve it.</p>","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of acetylcholinesterase inhibitors in the logopenic variant of primary progressive aphasia.","authors":"Julie Carrier-Auclair,Monica Lavoie,Maud Tastevin,Robert Laforce","doi":"10.1159/000540932","DOIUrl":"https://doi.org/10.1159/000540932","url":null,"abstract":"INTRODUCTIONFor over twenty-five years, cholinesterase inhibitors (ChEIs) have been the main symptomatic treatment for Alzheimer's disease (AD). Several meta-analyses have supported their efficacy in various neurocognitive, functional, and behavioral aspects of amnestic AD. Over 86% of cases of the language variant AD are caused by a similar pathologic process than AD, yet no study has examined the efficacy of ChEIs in this AD variant. We aimed to explore the efficacy of ChEIs in the treatment of language AD by comparing their evolution on the MMSE to that of treated amnestic AD patients.METHODSA retrospective chart review was performed in forty-five patients with language AD and fifty-two patients with amnestic AD. Both groups were similar regarding age, level of education, and onset of symptoms. Drug history, MMSE scores, functional and neuropsychiatric symptoms were collected on several time points before and after the introduction of ChEIs. Data was analysed using ANOVA and a generalized linear mixed model.RESULTSPatients with language AD showed a similar trajectory of decline than amnestic AD patients on serial MMSEs up to twenty-four months after the introduction of ChEIs. In language AD patients, ChEIs had a significant impact on activities of daily life (ADLs), but not instrumental activities of daily living (IADLs), and neuropsychiatric symptoms remained stable over time.CONCLUSIONThis study provides preliminary evidence for efficacy of ChEIs in patients with language AD and suggests similar benefits to those seen in amnestic AD patients, hence reassuring patients and their physicians.","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":"13 1","pages":"1-21"},"PeriodicalIF":2.4,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142194182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Perceived Stress and Motoric Cognitive Risk Syndrome in an Elderly Population: Rugao Longevity and Aging Study.","authors":"Yuan-Fei Cao, Guo-Ping Shi, Hui Zhang, Meng-Zhen Sun, Zheng-Dong Wang, Xue-Feng Chu, Jiang-Hong Guo, Xiao-Feng Wang","doi":"10.1159/000537937","DOIUrl":"10.1159/000537937","url":null,"abstract":"<p><strong>Introduction: </strong>Previous studies have indicated a correlation between perceived stress and cognitive decline. However, it remains unknown whether high levels of perceived stress can result in motoric cognitive risk (MCR) syndrome. This study investigated the relationship between perceived stress and MCR in a community-based population.</p><p><strong>Methods: </strong>The study cohort comprised 852 elderly individuals from the Rugao Longitudinal Aging Cohort. Perceived stress was assessed using the 10-item Perceived Stress Scale (PSS-10), while MCR was defined as the coexistence of subjective memory complaints (SMCs) and slow gait speed.</p><p><strong>Results: </strong>The average age of the study participants is 79.84 ± 4.34 years. The mean score of PSS-10 among participants is 10.32 (range = 0-33; [SD] = 5.71), with a median score of 10.00 (6.00, 14.00). The prevalence of MCR is 9.3%. In the logistic regression analysis, for each 1-SD (5.71) increase in the global PSS-10 score, the risk of MCR increased by 40% (95% CI 1.09-1.80). Additionally, in the aspect of two components of MCR, with a 1-SD increase (5.71) in the global PSS-10 score, there was a 50% (95% CI 1.29-1.75) increase in the risk of SMCs and a 27% (95% CI 1.04-1.55) increase in the risk of slow gait speed. In terms of specific walking speed, there was a reverse correlation between the global PSS-10 score and walking speed (r = -0.14, p &lt; 0.001).</p><p><strong>Conclusions: </strong>This study provided preliminary evidence that high levels of perceived stress were associated with the risk of MCR in a community-dwelling population.</p>","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":" ","pages":"74-82"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11098018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139971264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Performance of Five Cognitive Screening Tests in a Large Sample of Seniors.","authors":"Jurij Dreo, Jan Jug, Tisa Pavlovčič, Ajda Ogrin, Anita Demšar, Barbara Aljaž, Filip Agatić, Uros Marusic","doi":"10.1159/000540225","DOIUrl":"10.1159/000540225","url":null,"abstract":"<p><strong>Introduction: </strong>Recent introductions of disease-modifying treatments for Alzheimer's disease have re-invigorated the cause of early dementia detection. Cognitive \"paper and pencil\" tests represent the bedrock of clinical assessment, because they are cheap, easy to perform, and do not require brain imaging or biological testing. Cognitive tests vary greatly in duration, complexity, sociolinguistic biases, probed cognitive domains, and their specificity and sensitivity of detecting cognitive impairment (CI). Consequently, an ecologically valid head-to-head comparison seems essential for evidence-based dementia screening.</p><p><strong>Method: </strong>We compared five tests: Montreal cognitive assessment (MoCA), Alzheimer's disease assessment scale-cognitive subscale (ADAS), Addenbrooke's cognitive examination (ACE-III), euro-coin handling test (Eurotest), and image identification test (Phototest) on a large sample of seniors (N = 456, 77.9 ± 8 years, 71% females). Their specificity and sensitivity were estimated in a novel way by contrasting each test's outcome to the majority outcome across the remaining tests (comparative specificity and sensitivity calculation [CSSC]). This obviates the need for an a priori gold standard such as a clinically clear-cut sample of dementia/MCI/controls. We posit that the CSSC results in a more ecologically valid estimation of clinical performance while precluding biases resulting from different dementia/MCI diagnostic criteria and the proficiency in detecting these conditions.</p><p><strong>Results: </strong>There exists a stark trade-off between behavioral test specificity and sensitivity. The test with the highest specificity had the lowest sensitivity, and vice versa. The comparative specificities and sensitivities were, respectively: Phototest (97%, 47%), Eurotest (94%, 55%), ADAS (90%, 68%), ACE-III (72%, 77%), MoCA (55%, 95%).</p><p><strong>Conclusion: </strong>Assuming a CI prevalence of 10%, the shortest (∼3 min) and the simplest instrument, the Phototest, was shown to have the best overall performance (accuracy 92%, PPV 66%, NPV 94%).</p>","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":" ","pages":"289-298"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effectiveness of the Case Manager-Centered Collaborative Care Model with Computer-Assisted Assessment on Quality Indicators for the Care of Dementia.","authors":"Yen-Jen Chen, Wen-Fu Wang, Ming-Che Chang, Kai-Ming Jhang","doi":"10.1159/000536646","DOIUrl":"10.1159/000536646","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to investigate the influence of case management and its corresponding computer-assisted assessment system on the quality improvement of dementia care.</p><p><strong>Methods: </strong>This observational study enrolled 2029 patients and their caregivers at Changhua Christian Hospital in Taiwan. Physicians who made the diagnosis of dementia would introduce the patient and caregiver dyad to the case manager-centered collaborative care team after obtaining agreement. The achievement rates of 11 quality indicators (QIs) comprising timely diagnostic evaluations, regular screens of cognition and neuropsychiatric symptoms, caregiver support, and proper medication prescriptions were counted. Different timeframes (≤4 months, 4 months-1 year, 1-2 years, 2-3 years, or ≥3 years) from diagnosis of dementia to collaborative care intervention were compared.</p><p><strong>Results: </strong>A significantly higher attainment rate was achieved for patients with earlier entry into the collaborative team model, including QIs about timely diagnosis and regular screening, and caregiver support. The QIs regarding dementia medication prescriptions and documentation of the risk of antipsychotics remained similar regardless of the time of entry into the model. The completion rates of QIs also improved after the information system was launched.</p><p><strong>Conclusions: </strong>Physician-case manager co-management in the setting of a collaborative care model with a computer-assisted assessment system helps improve QI achievement for dementia care.</p>","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":" ","pages":"29-36"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139691378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multicenter, Open-Label, Prospective Study Shows Safety and Therapeutic Benefits of a Defined Ginkgo Biloba Extract for Adults with Major Neurocognitive Disorder.","authors":"Debashish Chowdhury, Ajit Kumar Roy, V Radhika Reddy, Yogesh Kumar Gupta, Pushkar Nigam, Robert Hoerr","doi":"10.1159/000540385","DOIUrl":"10.1159/000540385","url":null,"abstract":"<p><strong>Introduction: </strong>The safety and therapeutic effects of Gingko biloba extract EGb 761® to treat cognitive decline have been demonstrated in numerous clinical trials. However, trials in Indian populations have been lacking.</p><p><strong>Methods: </strong>This open-label, multicenter, single-arm, phase IV trial enrolled 150 patients aged ≥50 years with major neurocognitive disorder due to Alzheimer's disease, major vascular neurocognitive disorder, or mixed forms of both according to the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria and a Mini-Mental State Examination (MMSE) score of 12-24. Patients took 120 mg EGb 761® twice daily for 18 weeks. Therapeutic effects were assessed by CERAD constructional praxis and recall of constructional praxis (CERAD CP, CERAD recall of CP), Trail-Making Test (TMT), Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD), Clinical Global Impressions (CGI) scale, and 11-point box scales for tinnitus and vertigo. Safety assessment was based on the occurrence of adverse events as well as changes in clinical, laboratory, and functional parameters.</p><p><strong>Results: </strong>After 18 weeks, significant improvements compared to baseline were found in constructional praxis (CERAD CP, p < 0.0001), memory (CERAD recall of CP, p < 0.0001), speed and executive functioning (TMT A, p < 0.0001; TMT B, p < 0.0001), and behavioral symptoms (BEHAVE-AD, p < 0.0001). Forty-five adverse events were reported in 33 (22.0%) patients in total, including ten presumed adverse drug reactions in 9 (6.0%) patients. Headache and diarrhea of mild-to-moderate severity were the most frequent events. Two serious adverse events, both considered unrelated to the study drug, occurred in 2 (1.3%) patients.</p><p><strong>Conclusion: </strong>This study confirmed the favorable safety profile and suggested therapeutic benefits of EGb 761® in Indian patients with major neurocognitive disorder.</p>","PeriodicalId":11126,"journal":{"name":"Dementia and Geriatric Cognitive Disorders","volume":" ","pages":"299-309"},"PeriodicalIF":2.2,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}